Brokerages Anticipate Avenue Therapeutics Inc (ATXI) to Announce -$0.47 EPS

Analysts expect that Avenue Therapeutics Inc (NASDAQ:ATXI) will announce earnings of ($0.47) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Avenue Therapeutics’ earnings. The lowest EPS estimate is ($0.62) and the highest is ($0.38). Avenue Therapeutics reported earnings per share of ($0.63) during the same quarter last year, which suggests a positive year over year growth rate of 25.4%. The company is expected to issue its next earnings results on Thursday, March 7th.

According to Zacks, analysts expect that Avenue Therapeutics will report full year earnings of ($2.23) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.10). For the next fiscal year, analysts forecast that the company will report earnings of ($1.98) per share, with EPS estimates ranging from ($2.72) to ($1.55). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Avenue Therapeutics.

ATXI has been the subject of a number of recent analyst reports. ValuEngine raised Avenue Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Oppenheimer set a $8.00 target price on Avenue Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Avenue Therapeutics in a research report on Wednesday, August 15th.

Shares of NASDAQ:ATXI opened at $5.39 on Friday. Avenue Therapeutics has a fifty-two week low of $2.08 and a fifty-two week high of $6.00. The stock has a market capitalization of $57.47 million, a price-to-earnings ratio of -3.05 and a beta of -2.35.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Further Reading: What is a Stop Order?

Get a free copy of the Zacks research report on Avenue Therapeutics (ATXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avenue Therapeutics (NASDAQ:ATXI)

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply